Public Version
`
`
`UNITED STATES INTERNATIONAL TRADE COMMISSION
`
`Washington, D.C.
`
`
`In the Matter of
`
`CERTAIN VAPORIZER CARTRIDGES AND
`COMPONENTS THEREOF
`
`
`Inv. No. 337-TA-1211
`
`
`
`
`ORDER NO. 46:
`
`
`
`
`I.
`
`BACKGROUND
`
`INITIAL DETERMINATION GRANTING JOINT MOTION
`TO TERMINATE THE INVESTIGATION WITH RESPECT
`TO RESPONDENT PRICE POINT NY [MOTION DOCKET
`NO. 1211-048]
`
`(February 2, 2021)
`
`The Commission instituted this Investigation on August 14, 2020. 85 Fed. Reg. 49679
`
`(Aug. 14, 2020). The Investigation was instituted based upon a Complaint filed on July 10, 2020
`
`by Complainant Juul Labs, Inc. (“Complainant” or “JLI”) against, inter alia, Respondent Price
`
`Point NY (“Respondent” or “Price Point,” and with Complainant, the “Settling Parties”).1 (See,
`
`e.g., Compl. at ¶¶ 14, 17.). Complainant accused Price Point of violating Section 337 of the
`
`Tariff Act of 1930, as amended (19 U.S.C. § 1337), based on the sale for importation into the
`
`United States, the importation into the United States, or the sale after importation into the United
`
`States of products alleged to infringe four (4) U.S. design patents (“Asserted Design Patents”).
`
`(Compl. at ¶ 10.).
`
`On January 11, 2021, pursuant to Commission Rule 210.21(c)(1)(ii), JLI and Price Point
`
`filed a confidential and a public version of their joint motion to terminate this Investigation
`
`
`1 The Complaint was supplemented on July 21, 2020 and July 31, 2020. (See Doc. ID Nos. 715095 (July
`21, 2020), 716127 (July 31, 2020).). The supplements did not materially alter the substance of the
`Complaint so as to affect this outcome.
`
`Page 1 of 11
`
`

`

`Public Version
`
`
`(“Motion”) with respect to Price Point based upon a consent order stipulation (“Stipulation”) and
`
`a proposed consent order (“Proposed Order”). (Motion Docket No. 1211-048.).
`
`On January 21, 2021, Commission Investigative Staff (“Staff”) filed a response (“Staff
`
`Response”) in support of the confidential and public versions of the Settling Parties’ Motion.
`
`(Doc. ID No. 731415 (Jan. 21, 2021).).
`
`II.
`
`APPLICABLE LAW
`
`Commission Rule 210.21(a)(2) provides that “[a]ny party may move at any time to
`
`terminate an investigation in whole or in part as to any or all respondents on the basis of a . . .
`
`consent order.” 19 C.F.R. § 210.21(a)(2). A motion to terminate on the basis of a consent order
`
`must be submitted “with a stipulation that includes a proposed consent order.” 19 C.F.R.
`
`§ 210.21(c)(1)(ii). In addition, such a motion must include: (i) “copies of any licensing or other
`
`settlement agreement, any supplemental agreements;”2 and (ii) “a statement that there are no
`
`other agreements, written or oral, express or implied between the parties concerning the subject
`
`matter of the investigation.” 19 C.F.R. § 210.21(c).
`
`Commission policy generally “favors settlement to avoid needless litigation and to
`
`conserve public resources.” Certain Access Control Sys. and Components Thereof, Inv. No. 337-
`
`TA-1016, Order No. 36 at 3 (Oct. 17, 2017). Termination based on a consent order is routinely
`
`granted when the requirements for a consent order are satisfied by the participating parties. See,
`
`e.g., Certain Insect Traps, Inv. No. 337-TA-498, Order No. 9 at 5 (Apr. 9, 2004).
`
`Commission Rule 210.21(c)(3)(i) provides that a consent order stipulation must include
`
`the following:
`
`(A) An admission of all jurisdictional facts;
`
`2 If the license or other settlement agreement contains confidential business information, a public version
`of the agreement must also be attached. 19 C.F.R. § 210.21(c).
`
`Page 2 of 11
`
`

`

`Public Version
`
`
`
`
`
`
`(B) A statement identifying the asserted patent claims, copyright, trademark, mask work,
`boat hull design, or unfair trade practice, and whether the stipulation calls for cessation of
`importation, distribution, sale, or other transfers (other than exportation) of subject
`articles in the United States and/or specific terms relating to the disposition of existing
`U.S. inventories of subject articles[;]
`
`(C) An express waiver of all rights to seek judicial review or otherwise challenge or
`contest the validity of the consent order;
`
`(D) A statement that the signatories to the consent order stipulation will cooperate with
`and will not seek to impede by litigation or other means the Commission’s efforts to
`gather information under subpart I of this part;
`
`(E) A statement that the enforcement, modification, and revocation of the consent order
`will be carried out pursuant to subpart I of this part, incorporating by reference the
`Commission’s Rules of Practice and Procedure;
`
`(F) A statement that the signing thereof is for settlement purposes only and does not
`constitute admission by any respondent that an unfair act has been committed, if
`applicable; and
`
`(G) A statement that the consent order shall have the same force and effect and may be
`enforced, modified, or revoked in the same manner as is provided in section 337 of the
`Tariff Act of 1930 and this part for other Commission actions, and the Commission may
`require periodic compliance reports pursuant to subpart I of this part to be submitted by
`the person entering into the consent order stipulation.
`
`19 C.F.R. § 210.21(c)(3)(i).
`
`In addition, when alleged unfair acts relate to intellectual property rights, a consent order
`
`stipulation must also include the following:
`
`(A) A statement that the consent order shall not apply with respect to any claim of any
`intellectual property right that has expired or been found or adjudicated invalid or
`unenforceable by the Commission or a court or agency of competent jurisdiction,
`provided that such finding or judgment has become final and nonreviewable; [and]
`
`(B) A statement that each signatory to the stipulation who was a respondent in the
`investigation will not seek to challenge the validity of the intellectual property right(s), in
`any administrative or judicial proceeding to enforce the consent order.
`
`19 C.F.R. § 210.21(c)(3)(ii).
`
`Finally, a consent order stipulation must include a proposed consent order that, pursuant
`
`Page 3 of 11
`
`

`

`Public Version
`
`
`to Commission Rule 210.21(c)(4), includes the following:
`
`(i) A statement of the identity of complainant, the respondent, and the subject articles,
`and a statement of any allegation in the complaint that the respondents sell for
`importation, import, or sell after importation the subject articles in violation of section
`337 by reason of asserted patent claims, copyright, trademark, mask work, boat hull
`design, or unfair trade practice;
`
`(ii) A statement that the respondents have executed a consent order stipulation (but the
`consent order shall not contain the terms of the stipulation);
`
`(iii) A statement that the respondent shall not sell for importation, import, or sell after
`importation the subject articles, directly or indirectly, and shall not aid, abet, encourage,
`participate in, or induce the sale for importation, the importation, or the sale after
`importation except under consent, license from the complainant, or to the extent
`permitted by the settlement agreement between complainant and respondent;
`
`(iv) A statement, if applicable, regarding the disposition of existing U.S. inventories of
`the subject articles[;]
`
`(v) A statement, if applicable, whether the respondent would be ordered to cease and
`desist from importing and distributing articles covered by the asserted patent claims,
`copyright, trademark, mask work, boat hull design, or unfair trade practice;
`
`(vi) A statement that respondent shall be precluded from seeking judicial review or
`otherwise challenging or contesting the validity of the Consent Order;
`
`(vii) A statement that respondent shall cooperate with and shall not seek to impede by
`litigation or other means the Commission’s efforts to gather information under subpart I
`of the Commission’s Rules of Practice and Procedure, 19 CFR part 210;
`
`(viii) A statement that [r]espondent and its officers, directors, employees, agents, and any
`entity or individual acting on its behalf and with its authority shall not seek to challenge
`the validity or enforceability of the claims of the asserted patent claims, copyright,
`trademark, mask work, boat hull design, or unfair trade practice in any administrative or
`judicial proceeding to enforce the Consent Order;
`
`(ix) A statement that when the patent, copyright, trademark, mask work, boat hull design,
`or unfair trade practice expires the Consent Order shall become null and void as to such;
`
`(x) A statement that if any claim of the patent, copyright, trademark, mask work, boat
`hull design, or other unfair trade practice is held invalid or unenforceable by a court or
`agency of competent jurisdiction or as to any articles that has been found or adjudicated
`not to infringe the asserted right in a final decision, no longer subject to appeal, this
`Consent Order shall become null and void as to such invalid or unenforceable claim; and
`
`
`Page 4 of 11
`
`

`

`Public Version
`
`
`(xi) A statement that the investigation is hereby terminated with respect to the
`respondent; provided, however, that enforcement, modification, or revocation of the
`Consent Order shall be carried out pursuant to Subpart I of the Commission’s Rules of
`Practice and Procedure, 19 CFR part 210.
`
`
`19 C.F.R. § 210.21(c)(4).
`
`The proposed consent order may not include terms beyond or inconsistent with those set
`
`forth by Commission Rule 210.21(c)(4). Id.
`
`III. ANALYSIS
`
`The Motion requesting termination of the Investigation with respect to all asserted claims
`
`against Price Point should be granted because Price Point satisfied the requirements set forth in
`
`Commission Rules 210.21(c)(3) and 210.21(c)(4).
`
`Price Point has executed a Stipulation, attached as Exhibit A to the Motion, that complies
`
`with Commission Rule 210.21(c)(3). (Mot. at Ex. A.). The Stipulation incorporates a Proposed
`
`Order, attached as Exhibit B to the Motion, that complies with Commission Rule 210.21(c)(4).
`
`(Id. at Ex. B.). The Proposed Order does not appear to have terms beyond, or materially
`
`inconsistent with, those provided for in Commission Rule 210.21(c)(4). (Id.). The Settling
`
`Parties have also attached to their Motion confidential and non-confidential (redacted) copies of
`
`their Settlement Agreement, as Exhibit C. (Id. at Ex. C.). Finally, the Settling Parties state in the
`
`Motion that “there are no other agreements, written or oral, express or implied, relating to the
`
`subject matter of this Investigation.” (Mot. at 1.). The Stipulation, Proposed Order, and
`
`Settlement Agreement are attached hereto as Exhibits A, B, and C, respectively.
`
`A.
`
`Stipulation
`
`In compliance with 19 C.F.R. § 210.21(c)(3)(i)(A), Price Point stipulates that the
`
`Commission has in rem jurisdiction over the subject matter of this Investigation, subject matter
`
`jurisdiction over the allegations set forth in Complainant’s Complaint, and personal jurisdiction
`
`Page 5 of 11
`
`

`

`Public Version
`
`
`over it for purposes of the Consent Order. (Stipulation, p. 2 at ¶ 1.).
`
`In compliance with 19 C.F.R. § 210.21(c)(3)(i)(B), the Stipulation identifies the asserted
`
`patent rights and provides that:
`
`Price Point . . . will not sell for importation, import into the United States or sell in
`the United States after importation . . . [certain] vaporizer cartridges and
`components thereof that infringe any of the claims of the Asserted Claims, except
`under consent or license from JLI.3
`
`(Id., p. 1, p. 2 at ¶ 2.).
`
`In compliance with 19 C.F.R. § 210.21(c)(3)(i)(C), Price Point stipulates that it
`
`“expressly waives all right to seek judicial review or otherwise challenge the validity of the
`
`Consent Order.” (Id., p. 2 at ¶ 4.).
`
`In compliance with 19 C.F.R. § 210.21(c)(3)(i)(D), Price Point stipulates that it “will
`
`cooperate with and will not seek to impede by litigation or other means the Commission’s efforts
`
`to gather information under Subpart I of the Commission’s Rules of Practice and Procedure, 19
`
`C.F.R. Subchapter C, Part 210.” (Id., p. 2 at ¶ 5.).
`
`In compliance with 19 C.F.R. § 210.21(c)(3)(i)(E), Price Point stipulates that
`
`“enforcement, modification and revocation of the Consent Order will be carried out pursuant to
`
`Subpart I of the Commission’s Rule of Practice and Procedure, 19 C.F.R. Subchapter C, Part
`
`210.” (Id., p. 3 at ¶ 6.).
`
`In compliance with 19 C.F.R. § 210.21(c)(3)(i)(F), Price Point stipulates that “[t]he
`
`signing of this Stipulation is for settlement purposes only and does not constitute admission by
`
`[Price Point] that an infringement of the Asserted Claims and/or an unfair act has been
`
`committed.” (Id., p. 3 at ¶ 7.).
`
`
`3 “Asserted Claims” was defined in page 1 of the Stipulation.
`
`Page 6 of 11
`
`

`

`Public Version
`
`
`In compliance with 19 C.F.R. § 210.21(c)(3)(i)(G), Price Point stipulates that “[t]he
`
`Consent Order shall have the same force and effect and may be enforced, modified, or revoked in
`
`the same manner as is provided in section 337 of the Tariff Act of 1930 and for this part for other
`
`Commission actions” and that “the Commission may require periodic compliance reports
`
`pursuant to subpart I of this part to be submitted by Price Point.” (Id., p. 3 at ¶ 8.).
`
`In compliance with 19 C.F.R. § 210.21(c)(3)(ii)(A), Price Point stipulates that “if any
`
`asserted patent claim has expired or is held invalid or unenforceable by a court or agency of
`
`competent jurisdiction or if any article has been found or adjudicated not to infringe the asserted
`
`right in a final decision, no longer subject to appeal, this Consent Order shall become null and
`
`void as to such expired, invalid, or unenforceable claim or as to any adjudicated article.” (Id., p.
`
`3 at ¶ 9.).
`
`In compliance with 19 C.F.R. § 210.21(c)(3)(ii)(B), Price Point stipulates that it “will not
`
`seek to challenge the validity or enforceability of the patents that form the basis for the complaint
`
`in any administrative or judicial proceeding to enforce the Consent Order.” (Id., p. 3 at ¶ 10.).
`
`The Stipulation thus meets the requirements of Commission Rule 210.21(c)(3). 19
`
`C.F.R. § 210.21(c)(3).
`
`B.
`
`Proposed Order
`
`In compliance with 19 C.F.R. § 210.21(c)(4)(i), the Proposed Order identifies: (i)
`
`Complainant Juul Labs, Inc.; (ii) Respondent Price Point; and (iii) the subject articles as certain
`
`vaporizer cartridges and components thereof that are alleged to infringe U.S. Design Patent No.
`
`D842,536 (“the ’D536 patent”), U.S. Design Patent No. D858,870 (“the ’D870 patent”), U.S.
`
`Design Patent No. D858,869 (“the ’D869 patent”), and U.S. Design Patent No. D858,868 (“the
`
`’D868 patent”). (See Proposed Order, p. 1.).
`
`Page 7 of 11
`
`

`

`Public Version
`
`
`In compliance with 19 C.F.R. § 210.21(c)(4)(ii), the Proposed Order provides that Price
`
`Point has executed a consent order stipulation. (Id.).
`
`In compliance with 19 C.F.R. § 210.21(c)(4)(iii), the Proposed Order provides that Price
`
`Point “shall not sell for importation, import into the United States, or sell in the United States
`
`after importation, directly or indirectly, or aid, abet, encourage, participate in, or induce the sale
`
`for importation, importation into the United States or sale in the United States after importation
`
`of certain vaporizer cartridges and components thereof that infringe any of the claims of the
`
`Asserted Claims, except under consent or license from JLI.” (Id., p. 2 at ¶ 1.).
`
`The Proposed Order provides that Price Point does not have any existing U.S. inventories
`
`of vaporizer cartridges and components thereof. (Id., p. 2 at ¶ 6.).
`
`In compliance with 19 C.F.R. § 210.21(c)(4)(vi), the Proposed Order provides that Price
`
`Point shall be precluded from seeking judicial review or otherwise challenging or contesting the
`
`validity of the Consent Order. (Id., p. 2 at ¶ 3.).
`
`In compliance with 19 C.F.R. § 210.21(c)(4)(vii), the Proposed Order provides that Price
`
`Point shall cooperate with and shall not seek to impede by litigation or other means the
`
`Commission’s efforts to gather information under Subpart I of the Commission’s Rules of
`
`Practice and Procedure, 19 C.F.R. Part 210. (Id., p. 2 at ¶ 4.).
`
`In compliance with 19 C.F.R. § 210.21(c)(4)(viii), the Proposed Order provides that Price
`
`Point and its officers, directors, employees, agents and any entity or individual acting on its
`
`behalf and with its authority shall not seek to challenge the validity or enforceability of the
`
`Asserted Claims in any administrative or judicial proceeding to enforce the Consent Order. (Id.,
`
`p. 2 at ¶ 5.).
`
`In compliance with 19 C.F.R. § 210.21(c)(4)(ix), the Proposed Order provides that upon
`
`Page 8 of 11
`
`

`

`Public Version
`
`
`expiration of any of the Asserted Design Patents, the Consent Order “shall become null and void
`
`as to such expired patent.” (Id., p. 2 at ¶ 7.).
`
`In compliance with 19 C.F.R. § 210.21(c)(4)(x), the Proposed Order provides that if any
`
`claim of the Asserted Design Patents is held invalid or unenforceable by a court or agency of
`
`competent jurisdiction or if any article has been found or adjudicated not to infringe the asserted
`
`right in a final decision, no longer subject to appeal, this Consent Order shall become null and
`
`void as to such invalid or unenforceable claim or adjudicated article. (Id., p. 3 at ¶ 8.).
`
`In compliance with 19 C.F.R. § 210.21(c)(4)(xi), the Proposed Order states that the
`
`Investigation is terminated with respect to Price Point, provided, however, that enforcement,
`
`modification, or revocation of the Consent Order shall be carried out pursuant to Subpart I of the
`
`Commission’s Rules of Practice and Procedure, 19 C.F.R. Part 210. (Id., p. 3 at ¶ 10.).
`
`The Proposed Order thus meets the requirements of Commission Rule 210.21(c)(4). 19
`
`C.F.R. § 210.21(c)(4).
`
`C.
`
`Settlement Agreement
`
`In addition to the Stipulation and Proposed Order, the Settling Parties also have entered
`
`into a Settlement Agreement (Exhibit C). The Settling Parties’ public version of the Motion,
`
`filed on January 11, 2021, has attached a redacted version of their Settlement Agreement that
`
`complies with 19 C.F.R. § 201.6(a). (Doc. ID No. 730240 (Jan. 11, 2021).).
`
`D.
`
`Public Interest
`
`Commission Rules require consideration and appropriate findings with respect to the
`
`potential impact of any settlement or consent order on the public interest. 19 C.F.R.
`
`§§ 210.50(b)(2), 210.21(c)(2)(ii). The Settling Parties have not submitted any information that
`
`would indicate that termination of this Investigation with respect to Respondent Price Point on
`
`Page 9 of 11
`
`

`

`Public Version
`
`
`the basis of the Proposed Order and Settlement Agreement would be contrary to the public health
`
`and welfare, competitive conditions in the U.S. economy, the production of like or directly
`
`competitive articles in the United States, or U.S. consumers. See 19 U.S.C. § 1337(d). The
`
`public interest generally favors termination of an investigation when it will avoid needless
`
`litigation and conserve public and private resources. See, e.g., Certain Electronic Paper Towel
`
`Dispensing Devices and Components Thereof, Inv. No. 337-TA-718, Order No. 25 at 4 (Dec. 1,
`
`2010); Certain Compact Disc and DVD Holders, Inv. No. 337-TA-482, Order No. 11 at 3 (Mar.
`
`7, 2003) (“termination of litigation under these circumstances as an alternative method of dispute
`
`resolution is generally in the public interest.”); accord Certain Gel-Filled Wrist Rests and Prods.
`
`Containing Same, Inv. No. 337-TA-456, Order No. 16, at 5 (May 21, 2002). Thus, there is no
`
`apparent public interest reason why the Investigation should not be terminated.
`
`V.
`
`RECOMMENDATION
`
`Because I know of no extraordinary circumstances that would prevent termination of this
`
`Investigation with respect to Price Point, it is my Initial Determination that for good cause
`
`shown, and because it is in the public interest, that this Investigation be terminated with respect
`
`to Price Point, and that Motion Docket No. 1211-048 should be granted.
`
`This Initial Determination is hereby certified to the Commission. Pursuant to 19 C.F.R.
`
`§ 210.42(h), this Initial Determination shall become the determination of the Commission unless
`
`a party files a petition for review of the Initial Determination pursuant to 19 C.F.R. § 210.43(a),
`
`or the Commission orders on its own motion a review of the Initial Determination or certain
`
`issues herein pursuant to 19 C.F.R. § 210.44.
`
`SO ORDERED.
`
`
`
`
`
`
`
`
`
`Page 10 of 11
`
`

`

`Public Version
`
`
`
`
`
`Admini trative Law Judge
`
`Page 11 of 11
`
`

`

`EXHIBIT A
` Consent Order Stipulation
`
`

`

`UNITED STATES INTERNATIONAL TRADE COMMISSION
`WASHINGTON, D.C.
`
`Before the Honorable MaryJoan McNamara
`Administrative Law Judge
`
`
`
`In the Matter of
`
`CERTAIN VAPORIZER CARTRIDGES
`AND COMPONENTS THEREOF
`
`
`
`
`
`
`
`
`
`Investigation No. 337-TA-1211
`
`CONSENT ORDER STIPULATION
`
`
`
`
`WHEREAS, the United States International Trade Commission on August 10, 2020 (85
`
`Fed. Reg. 49,679 (Aug. 14, 2020)), instituted the above-captioned investigation under Section
`
`337 of the Tariff Act of 1930, as amended, (19 U.S.C. § 1337) based upon complaint filed by
`
`Complainant Juul Labs, Inc.
`
`, which alleged unfair acts in the importation into the United
`
`States, the sale for importation into the United States, and the sale within the United States after
`
`importation of certain vaporizer cartridges and components thereof, by, among others,
`
`Respondent Price Point NY, ( Price Point NY ), in violation of Section 337 with respect to the
`
`sole claim of each of U.S. Patent Nos. D842,536
`
`D858,870
`
`D858,869
`
`D858,868
`
`
`
`Claims ;
`
`
`
`WHEREAS, Price Point NY is willing to accept entry of the Consent Order submitted
`
`concurrently herewith by the International Trade Commission and agrees to all waivers and other
`
`provisions as required by 19 C.F.R. § 210.21; and
`
`
`
`
`
`WHEREAS, Price Point NY agrees to all terms set forth in the Consent Order.
`
`
`
`

`

`
`
`IT IS HEREBY STIPULATED by Price Point NY in support of the Joint Motion for an
`
`Order Terminating the Investigation as to Price Point NY by Entry of a Consent Order as
`
`follows:
`
`
`
`1.
`
`The Commission has subject matter jurisdiction over this investigation. The
`
`Commission has in rem jurisdiction over the accused vaporizer cartridges and components
`
`thereof that are the subject of the complaint in this investigation. The Commission also has in
`
`personam jurisdiction over Price Point NY for purposes of this Stipulation and the proposed
`
`Consent Order by virtue of Price Point NY having appeared in this proceeding. Nothing in this
`
`Stipulation or the proposed Consent Order shall be construed as meaning that Price Point NY has
`
`submitted to the jurisdiction of any other court.
`
`
`
`2.
`
`Price Point NY, including its officers, directors, employees, agents, and any entity
`
`or individual acting on its behalf and with its authority, agrees, upon entry of the Consent Order,
`
`that it will not sell for importation, import into the United States or sell in the United States after
`
`importation, directly or indirectly, or aid, abet, encourage, participate in, or induce the sale for
`
`importation, importation into the United States or sale in the United States after importation of
`
`vaporizer cartridges and components thereof that infringe any of the claims of the Asserted
`
`Claims
`
`, except under consent or license from JLI.
`
`
`
`
`
`3.
`
`4.
`
`Price Point NY does not have any existing U.S. inventories of Subject Articles.
`
`Price Point NY expressly waives all right to seek judicial review or otherwise
`
`challenge the validity of the Consent Order.
`
`
`
`5.
`
`Price Point NY will cooperate with and will not seek to impede by litigation or
`
`other means the Commission's efforts to gather information under Subpart I of the Commission's
`
`Rules of Practice and Procedure, 19 C.F.R. Subchapter C, Part 210.
`
`
`
`2
`
`

`

`6.
`
`The enforcement, modification and revocation of the Consent Order will be
`
`carried out pursuant to Subpart I of the Commission's Rules of Practice and Procedure, 19 CPR.
`
`Subchapter C, Part 210.
`
`7.
`
`The signing of this Stipulation is for settlement purposes only and does not
`
`constitute admission by Price Point NY that an infringement of the Asserted Claims and/or an
`
`unfair act has been committed.
`
`8.
`
`The Consent Order shall have the same force and effect and may be enforced,
`
`modified, or revoked in the same manner as is provided in section 337 of the Tariff Act of 1930
`
`and this part
`
`for other Commission actions, and the Commission may require periodic
`
`compliance reports pursuant to subpart I of this part to be submitted by Price Point NY.
`
`9.
`
`The Consent Order shall not apply if any asserted patent claim has expired or is
`
`held invalid or unenforceable by a court or agency of competent jurisdiction or if any article has
`
`been found or adjudicated not to infringe the asserted right in a final decision, no longer subject
`to appeal,
`this Consent Order shall become null and void as to such expired,
`invalid, or
`
`unenforceable claim or as to any adjudicated article.
`
`10.
`
`Price Point NY will not seek to challenge the validity or enforceability of the
`
`patents that form the basis for the complaint in any administrative or judicial proceeding to
`
`enforce the Consent Order.
`
`11.
`
`This Consent Order Stipulation and Consent Order are in the public interest.
`
`IT IS SO STIPULATED.
`
`Date: 0% 0"\ l 3’\
`
`Price Point NY
`
`By:
`Its:
`
`\Aawna Kch \\
`2 E
`
`

`

`EXHIBIT B
` Proposed Consent Order
`
`

`

`UNITED STATES INTERNATIONAL TRADE COMMISSION
`WASHINGTON, D.C.
`
`Before the Honorable MaryJoan McNamara
`Administrative Law Judge
`
`
`In the Matter of
`
`CERTAIN VAPORIZER CARTRIDGES
`AND COMPONENTS THEREOF
`
`
`
`
`
`
`
`
`Investigation No. 337-TA-1211
`
`[PROPOSED] CONSENT ORDER
`
`The United States International Trade Commission on August 10, 2020 (85 Fed. Reg.
`
`
`
`49,679 (Aug. 14, 2020)), instituted the above-captioned investigation under Section 337 of the
`
`Tariff Act of 1930, as amended, (19 U.S.C. § 1337) naming numerous respondents, including
`
`Price Point NY Price Point NY
`
`Juul Labs,
`
`JLI
`
`importation into the United States, and the sale within the United States after importation of
`
`certain vaporizer cartridges and components thereof, by, among others, Respondent Price Point
`
`NY, in violation of Section 337 with respect to the sole claim of each of United States Patent
`
`Nos. D842,536
`
` D858,870
`
`D858,869
`
`D858,868
`
`Claims
`
`
`
`
`
`Price Point NY has executed a Consent Order Stipulation in which it agrees to the entry
`
`of this Consent Order and to all waivers and other provisions as required by Commission Rule of
`
`Practice and Procedure 210.21(c) (19 C.F.R. § 210.21(c)). JLI and Price Point NY have filed a
`
`Joint Motion to Terminate the Investigation as to Price Point NY based on a Consent Order.
`
`
`
`1
`
`

`

`
`
`
`
`IT IS HEREBY ORDERED THAT:
`
`1.
`
`Upon the entry of this Consent Order, Price Point NY shall not sell for
`
`importation, import into the United States, or sell in the United States after importation, directly
`
`or indirectly, or aid, abet, encourage, participate in, or induce the sale for importation,
`
`importation into the United States or sale in the United States after importation of certain
`
`vaporizer cartridges and components thereof that infringe any of the claims of the Asserted
`
`Claims
`
`, except under consent or license from JLI.
`
`
`
`2.
`
`This Consent Order shall be applicable to and binding upon Price Point NY, their
`
`officers, directors, agents, servants, attorneys, employees, affiliates, and all persons, firms, or
`
`corporations acting or claiming to act on its behalf or under its direction or authority.
`
`
`
`3.
`
`Price Point NY shall be precluded from seeking judicial review or otherwise
`
`challenging or contesting the validity of this Consent Order.
`
`
`
`4.
`
`Price Point NY shall cooperate with and shall not seek to impede by litigation or
`
`other means the Commission's efforts to gather information under Subpart I of the Commission's
`
`Rules of Practice and Procedure, 19 C.F.R. Part 210.
`
`
`
`5.
`
`Price Point NY and its officers, directors, employees, agents, and any entity or
`
`individual acting on its behalf and with its authority shall not seek to challenge the validity or
`
`enforceability of the Asserted Claims in any administrative or judicial proceeding to enforce the
`
`Consent Order.
`
`
`
`
`
`6.
`
`7.
`
`Price Point NY does not have any existing U.S. inventories of Subject Articles.
`
`When an Asserted Patent expires, this Consent Order shall become null and void
`
`as to such expired patent.
`
`
`
`2
`
`

`

`
`
`8.
`
`This Consent Order shall become null and void as to any claim of any intellectual
`
`property right that is held invalid or unenforceable by a court or agency of competent jurisdiction
`
`or as to any article that has been found or adjudicated not to infringe the asserted right in a final
`
`decision, no longer subject to appeal.
`
`
`
`9.
`
`The Commission has subject matter jurisdiction over this investigation. The
`
`Commission has in rem jurisdiction over the accused vaporizer cartridges and components
`
`thereof that are the subject of the complaint in this investigation. The Commission also has in
`
`personam jurisdiction over Price Point NY for purposes of this Stipulation and the proposed
`
`Consent Order by virtue of Price Point NY having appeared in this proceeding. Nothing in this
`
`Stipulation or the proposed Consent Order shall be construed as meaning that Price Point NY has
`
`submitted to the jurisdiction of any other court.
`
`
`
`10.
`
`This investigation is hereby terminated with respect to Price Point NY, provided,
`
`however, that enforcement, modification, or revocation of the Consent Order shall be carried out
`
`pursuant to Subpart I of the Commission's Rules of Practice and Procedure, 19 C.F.R. part 210.
`
`
`
`By Order of the Commission
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`___________________________
`
`Lisa A. Barton
`
`Secretary to the Commission
`
`Issued: ___________, 2020
`
`
`
`
`
`3
`
`

`

`
`
`EXHIBIT C
` Settlement Agreement
`
`

`

`PUBLIC — CONTAINS REDACTED MATERIAL
`
`CONFIDENTIAL SETTLENIENT AGREEMENT
`
`THIS SETTLEMENT AGREEMENT (the “Agreement”) is made this 30m day of
`December, 2020 (the “Effective Date”), between .1qu Labs, Inc. (“JLI”), a privately-held
`corporation organized and existing under the laws of the state of Delaware, with its principal
`place of business at 560 20th Street, San Francisco, California 94107, and Price Point NY, a
`privately—held corporation with its principal place of business at 500 Smith Street, Farmingdale,
`New York 11735. JLI and Price Point NY are individually referred to herein as a “Party,” and
`collectively as the “Parties.”
`
`WHEREAS, there are numerous sources for electronic nicotine delivery system
`(“ENDS”) cartridges and non-ENDS cartridges (including but not limited to cannabidiol
`(“CBD”) products, cartridges that do not contain any content when imported (“empty pods”), or
`others filled with non-nicotine products (such as caffeine, taurine, melatonin and chamomile)
`entering the United States that infringe JLI’s US. Patent Nos. D842,536; D858,870; D858,869;
`and D858,868 (“the Asserted Patents”), and it is extremely difficult to identify the actual sources
`of such unauthorized infringing products because infiinging entities have shown and are
`expected to continue to show, for example but without limitation, the ability to utilize a number
`of different companies, business names, and addresses for purposes of concealing their sales and
`importation of infringing products, and/or employ complex business arrangements, conduct
`business under multiple names, and/or form intricate arrays of confusingly similar affiliates;
`
`WHEREAS, unauthorized infringing Juul-compatible cartridges are typically
`manufactured, marketed, sold and imported into the US. in violation of applicable regulations;
`
`WHEREAS, in response to the rampant infringement of JLI’s intellectual property rights,
`JLI has been and remains engaged in diligent efforts to use the enforcement of its intellectual
`property rights when possible to disrupt and stop distribution of such infringing products,
`although the difficulties described above often make JLI’s efforts challenging and expensive;
`
`WHEREAS, on July 10, 2020, JLI filed a Complaint (the “1211 Complaint”) at the
`United States International Trade Commission (“ITC”)